Quick Answer
GUIDED THERAPEUTICS INC reported Total Revenue of $767.0 thousand for fiscal year 2025.
GUIDED THERAPEUTICS INC — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $767.0K +10857.1% |
$7.0K -92.9% |
$98.0K +653.8% |
$13.0K -84.0% |
$81.0K -20.6% |
$102.0K +183.3% |
| Net Income | -$3.20M -32.2% |
-$2.42M +30.7% |
-$3.49M +19.6% |
-$4.34M -109.7% |
-$2.07M -641.9% |
-$279.0K +85.5% |
| Diluted EPS | -$0.04 +20.0% |
-$0.05 +28.6% |
-$0.07 +53.3% |
-$0.15 +16.7% |
-$0.18 -350.0% |
-$0.04 +93.1% |
| Total Assets | $1.32M -3.9% |
$1.38M -17.4% |
$1.67M -50.4% |
$3.37M +65.0% |
$2.04M +51.1% |
$1.35M +14.4% |
| Cash and Equivalents | — | — | — | $2.31M +259.7% |
$643.0K +253.3% |
$182.0K -79.8% |
| Long-Term Debt | — | — | — | $0.00 -100.0% |
$820.0K +3465.2% |
$23.0K -99.6% |
| Stockholders Equity | -$6.01M -22.8% |
-$4.89M -28.5% |
-$3.81M -32.0% |
-$2.88M +47.1% |
-$5.45M +49.8% |
-$10.86M +35.9% |
| R&D Expense | $469.0K -10.8% |
$526.0K +130.7% |
$228.0K +196.1% |
$77.0K +11.6% |
$69.0K -51.7% |
$143.0K +17.2% |
| Operating Income | -$2.37M -12.5% |
-$2.11M +39.0% |
-$3.46M -3.7% |
-$3.33M -41.1% |
-$2.36M -124.5% |
-$1.05M -12.3% |
| Gross Profit | $571.0K +28450.0% |
$2.0K -94.4% |
$36.0K +152.9% |
-$68.0K -440.0% |
$20.0K -86.0% |
$143.0K +520.6% |
| Shares Outstanding | 86.15M +32.3% |
65.13M +20.4% |
54.10M +11.3% |
48.60M +255.4% |
13.67M +4.1% |
13.14M +395742.1% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $60.0K | — | -48.7% |
| Net Income | September 30, 2025 | -$742.0K | -13.5% | +8.5% |
| Diluted EPS | September 30, 2025 | -$0.01 | +0.0% | +0.0% |
| Total Assets | September 30, 2025 | $903.0K | -27.7% | -3.9% |
| Cash and Equivalents | September 30, 2023 | $731.0K | -72.9% | -46.2% |
| Long-Term Debt | September 30, 2022 | $0.00 | -100.0% | — |
| Stockholders Equity | September 30, 2025 | -$5.65M | -14.8% | -3.2% |
| R&D Expense | September 30, 2025 | $136.0K | +22.5% | +2.3% |
| Operating Income | September 30, 2025 | -$485.0K | +13.5% | +36.4% |
| Gross Profit | September 30, 2025 | $35.0K | — | -55.7% |
| Shares Outstanding | September 30, 2025 | 83.60M | +38.3% | +5.9% |
- GUIDED THERAPEUTICS INC reported Total Revenue of $767.0 thousand for fiscal year 2025.
- GUIDED THERAPEUTICS INC showed an increase of +10857.1% in Total Revenue compared to the prior fiscal year.
- GUIDED THERAPEUTICS INC reported Net Income of -$3.20 million for fiscal year 2025.
- GUIDED THERAPEUTICS INC showed a decrease of -32.2% in Net Income compared to the prior fiscal year.
- GUIDED THERAPEUTICS INC reported Diluted EPS of $0.04 per share (loss) for fiscal year 2025.
- GUIDED THERAPEUTICS INC showed an increase of +20.0% in Diluted EPS compared to the prior fiscal year.
- GUIDED THERAPEUTICS INC reported Total Assets of $1.32 million for fiscal year 2025.
- GUIDED THERAPEUTICS INC showed a decrease of -3.9% in Total Assets compared to the prior fiscal year.
- GUIDED THERAPEUTICS INC reported Cash and Equivalents of $2.31 million for fiscal year 2022.
- GUIDED THERAPEUTICS INC showed an increase of +259.7% in Cash and Equivalents compared to the prior fiscal year.
- GUIDED THERAPEUTICS INC reported Long-Term Debt of $0.00 for fiscal year 2022.
- GUIDED THERAPEUTICS INC showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- GUIDED THERAPEUTICS INC reported Stockholders Equity of -$6.01 million for fiscal year 2025.
- GUIDED THERAPEUTICS INC showed a decrease of -22.8% in Stockholders Equity compared to the prior fiscal year.
- GUIDED THERAPEUTICS INC reported R&D Expense of $469.0 thousand for fiscal year 2025.
- GUIDED THERAPEUTICS INC showed a decrease of -10.8% in R&D Expense compared to the prior fiscal year.
- GUIDED THERAPEUTICS INC reported Operating Income of -$2.37 million for fiscal year 2025.
- GUIDED THERAPEUTICS INC showed a decrease of -12.5% in Operating Income compared to the prior fiscal year.
- GUIDED THERAPEUTICS INC reported Gross Profit of $571.0 thousand for fiscal year 2025.
- GUIDED THERAPEUTICS INC showed an increase of +28450.0% in Gross Profit compared to the prior fiscal year.
- GUIDED THERAPEUTICS INC reported Shares Outstanding of 86.15 million shares for fiscal year 2025.
- GUIDED THERAPEUTICS INC showed an increase of +32.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: